首页> 中文期刊> 《药品评价》 >复方苦参注射液联合化疗治疗中晚期胃癌的疗效观察

复方苦参注射液联合化疗治疗中晚期胃癌的疗效观察

             

摘要

目的:观察复方苦参注射液联合化疗治疗中晚期胃癌的疗效及其毒副反应。方法:将80例中晚期胃癌患者随机分为治疗组和对照组各40例,治疗组给予复方苦参注射液以及ECF(表阿霉素+氟尿嘧啶+顺铂)治疗,对照组为单纯ECF治疗,治疗六周后观察两组近期疗效情况和药物毒副反应。结果:治疗组40例无CR,26例PR,有效率65%,对照组40例无CR,15例PR,有效率37.5%,两组比较有统计学显著性差异(P<0.05)。治疗组较对照组在白细胞、红细胞、血小板下降及胃肠道反应等毒副反应均有所改善。结论:复方苦参注射液联合ECF化疗治疗中晚期胃癌能够减轻中晚期胃癌患者的毒副反应,具有改善临床症状的效果。%Objective: To observe the clinical efficacy and toxicity of compound kushen (matrine) injection combined with chemotherapy for middle-advanced gastric cancer. Methods: 80 gastric cancer patients were randomly divided into therapeutic group and control group with 40 cases in each group. The therapeutic group was given compound matrine injection and ECF (epirubicin, fluorouracil andcisplatin), while the control group was only treated with ECF. After six weeks, curative effects and adverse reactions in each group were compared. Results:There were 26 cases of PR in the therapeutic group, with an efficiency of 65%, and 15 cases of PR in the control group, with an efficiency of 37.5%. There was significant difference between the two groups (P<0.05). Conclusion: Combining compound matrine injection with ECF chemotherapy in the treatment for gastric cancer could reduce the toxicity reactions and improve clinical symptoms in the patients.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号